The authors examined the percent change in body weight from randomization to week 72 (SURMOUNT-1, -2, and -3) or week 52 (SURMOUNT-4), as well as the proportions of participants achieving the ...

The findings are congruent with recently reported real-world data that found a 6.9% greater weight loss at 1 year with tirzepatide versus semaglutide. Average weight lost in SURMOUNT-5 was also ...

In the SURMOUNT-1 trial, obese patients without diabetes who received tirzepatide with monthly lifestyle counseling lost 20.9% of baseline weight at 72 weeks (versus 3.1% for placebo) with ...

When Lilly reported strong results from SURMOUNT-1 earlier this year, the drugmaker suggested it may be able to file for approval of tirzepatide in obesity before the end of this year. That won't ...

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

Image: Adobe Stock SURMOUNT-OSA consisted of two phase 3 trials in which adults with obesity and moderate or severe OSA were randomly assigned to once-weekly tirzepatide or placebo for 1 year.

SURMOUNT-OSA trials: Zepbound reduced apnea events by 62.8%, improving sleep apnea outcomes. CMS spokesperson said that Medicare Part D can only cover obesity drugs if they are FDA-approved for ...